TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19282611

Group type: COMPARATOR
Intervention: Patients without cardiac complications
Number of subjects: 4703

Group type: EXPERIMENTAL
Intervention: Patients with cardiac complications
Number of subjects: 4703

Group type: EXPERIMENTAL
Intervention: Patients with left ventricular hypertrophy (LVH)
Number of subjects: 4703

Group type: EXPERIMENTAL
Intervention: Patients with ischemic heart disease (IHD)
Number of subjects: 4703
Study: 17158003

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT) users
Number of subjects: 2181

Group type: COMPARATOR
Intervention: Control group (non-users of HT)
Number of subjects: 2181
Study: 14583744

Group type: EXPERIMENTAL
Intervention: CBD (400 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12510212

Group type: EXPERIMENTAL
Intervention: 50 microg transdermal estradiol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100 microg transdermal estradiol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 36
Study: 10658445

Group type: EXPERIMENTAL
Intervention: PGE1 alpha-ciclodestrina
Number of subjects: 299

Group type: COMPARATOR
Intervention: Reference group (no treatment)
Number of subjects: 299
Study: 7609170

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 1965403

Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 350397

Group type: EXPERIMENTAL
Intervention: Immunotherapy with bacillus Calmette‐Guérin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Corynebacterium parvum (C. parvum)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Combination chemotherapy (MOCA)
Number of subjects: 79
Study: 31443893

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention (MBRP) with at least four sessions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mindfulness practice time
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mindfulness practice time controlling for intervention timing, demographic characteristics, and other factors
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mindfulness practice time without minimum treatment dose requirement
Number of subjects: 72
Study: 27315106

Group type: EXPERIMENTAL
Intervention: Peer victimization (physical, relational, reputational)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Relational victimization
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Physical victimization
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Victimization type
Number of subjects: 131
Study: 25817373

Group type: EXPERIMENTAL
Intervention: Low-dose adenovirus type-5 vector-based Ebola vaccine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose adenovirus type-5 vector-based Ebola vaccine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23841997

Group type: EXPERIMENTAL
Intervention: Food associated with toys (snacks with toys)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Food alone (snacks without toys)
Number of subjects: 600
Study: 22055504

Group type: EXPERIMENTAL
Intervention: 150 mg/day resveratrol (resVida)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 19037040

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 800 mcg
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: Buccal misoprostol 800 mcg
Number of subjects: 966
Study: 16925756

Group type: EXPERIMENTAL
Intervention: Adjuvant luteinizing hormone-releasing hormone (LHRH) agonist in Study 1
Number of subjects: 327

Group type: COMPARATOR
Intervention: LHRH agonist monotherapy or combined androgen blockade in Study 2
Number of subjects: 327
Study: 14517191

Group type: EXPERIMENTAL
Intervention: Mibefradil (100 mg oral dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10740903

Group type: EXPERIMENTAL
Intervention: DHE focused on diet
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DHE focused on oral hygiene instruction (OHI) using fluoride toothpaste
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DHE by a combined diet and OHI message
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: DHE diet and OHI, at home, once a year only
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (no DHE)
Number of subjects: 228
Study: 8557129

Group type: EXPERIMENTAL
Intervention: Corticosteroids in patients with ovulatory factor
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Corticosteroids in patients with unexplained infertility
Number of subjects: 169
Study: 1410164

Group type: EXPERIMENTAL
Intervention: Nicotine (0.4, 0.6, and 0.8 mg subcutaneously)
Number of subjects: 70
Study: 3935346

Group type: EXPERIMENTAL
Intervention: Cyclo (His‐Pro), 400 micrograms intravenously
Number of subjects: 0
Study: 30681054

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study: 29016452

Group type: EXPERIMENTAL
Intervention: Intravitreal tamponades (silicone oil and gas)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no intravitreal tamponades)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Silicone oil tamponade
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Gas tamponade
Number of subjects: 73
Study: 25073857

Group type: EXPERIMENTAL
Intervention: Insulin Sensitization (IS)
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Insulin Provision (IP)
Number of subjects: 2056
Study: 24507437

Group type: EXPERIMENTAL
Intervention: FNAB performed by the radiologist alone (study group)
Number of subjects: 203

Group type: COMPARATOR
Intervention: FNAB performed by the radiologist with a cytopathologist (control group)
Number of subjects: 203
Study: 23195963

Group type: EXPERIMENTAL
Intervention: Oral enteric insulin 50 U
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral enteric insulin 100 U
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral enteric insulin 200 U
Number of subjects: 12

Group type: COMPARATOR
Intervention: NPH insulin 6 U
Number of subjects: 12
Study: 19241302

Group type: EXPERIMENTAL
Intervention: 100 microg misoprostol
Number of subjects: 162

Group type: COMPARATOR
Intervention: 200 microg misoprostol
Number of subjects: 162
Study: 17541030

Group type: EXPERIMENTAL
Intervention: Dispatcher-assisted CPR with AED operation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dispatcher-assisted CPR without AED operation
Number of subjects: 54
Study: 15385809

Group type: EXPERIMENTAL
Intervention: Basiliximab (two 20-mg doses on days 0 and 4) + Tacrolimus (0.15 mg/kg/day; target trough levels 10-15 ng/mL)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Basiliximab + Tacrolimus
Number of subjects: 50
Study: 11353902

Group type: EXPERIMENTAL
Intervention: Kidney transplantation (exposed-group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-transplanted women (non-exposed group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Relative risk of breast pathology occurrence
Number of subjects: 30
Study: 9714353

Group type: EXPERIMENTAL
Intervention: Modified Steinbrocker's (MS) radiological scoring method
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Larsen's (L) radiological scoring method
Number of subjects: 68

Group type: COMPARATOR
Intervention: Original Steinbrocker's (OS) radiological scoring method
Number of subjects: 68
Study: 8790563

Group type: EXPERIMENTAL
Intervention: Pre-S vaccine (12 micrograms, 24 micrograms, 48 micrograms)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pre-S vaccine (48 micrograms)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Pre-S vaccine (any dose)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Recombivax-HB (10 micrograms)
Number of subjects: 87
Study: 2924936

Group type: EXPERIMENTAL
Intervention: LH-timed intrauterine insemination
Number of subjects: 47

Group type: COMPARATOR
Intervention: LH-timed natural intercourse
Number of subjects: 47
Study: 29596853

Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice daily
Number of subjects: 80
Study: 24827938

Group type: EXPERIMENTAL
Intervention: 12-week simulated developmental horse-riding program (SDHRP) combined with fitness training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group with ADHD (no intervention)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Typically developing (TD) control group (no intervention)
Number of subjects: 48
Study: 26465164

Group type: EXPERIMENTAL
Intervention: Gsup (supervised)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Gobs (not supervised)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Gref (no exercise program)
Number of subjects: 87
Study: 24267730

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) 10 mg/d plus Exemestane (EXE) 25 mg/d
Number of subjects: 724

Group type: COMPARATOR
Intervention: Exemestane (EXE) 25 mg/d
Number of subjects: 724

Group type: EXPERIMENTAL
Intervention: Everolimus (EVE) plus Exemestane (EXE)
Number of subjects: 724
Study: 21603651

Group type: EXPERIMENTAL
Intervention: ADVAX 0.2 mg via electroporation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ADVAX 1 mg via electroporation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ADVAX 4 mg via electroporation
Number of subjects: 35

Group type: COMPARATOR
Intervention: ADVAX 4 mg via standard intramuscular injection
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline placebo via electroporation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ADVAX 4 mg via electroporation (third vaccination at week 36)
Number of subjects: 35
Study: 17473542

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 15064942

Group type: EXPERIMENTAL
Intervention: i.v. iron dextran
Number of subjects: 35

Group type: COMPARATOR
Intervention: oral iron
Number of subjects: 35
Study: 11996476

Group type: EXPERIMENTAL
Intervention: Vinorelbine 20 mg/m2 (or 15 mg/m2 if prior pelvic radiotherapy) combined with estramustine phosphate (EMP) at 280 mg orally tds for 3 days, then every other week after 8 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Vinorelbine and EMP regimen
Number of subjects: 23
Study: 9659028

Group type: EXPERIMENTAL
Intervention: mivacurium 0.02 mg.kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: normal saline (control)
Number of subjects: 40
Study: 8085286

Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 233

Group type: COMPARATOR
Intervention: High-performance liquid chromatography (HPLC)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody assays (MAAs)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: MAA values of 10, 15, and 20 micrograms/ml
Number of subjects: 233
Study: 2685221

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 788774

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stilboestrol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Testosterone propionate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29883983

Group type: EXPERIMENTAL
Intervention: Assisted Reproductive Technology (ART)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Spontaneous conception
Number of subjects: 381
Study: 25451608

Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 25
Study: 23057495

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (oxaliplatin 50 mg/m² on days 1, 8, 22, and 29; S-1 80 mg/m² per day on days 1-14 and 22-35)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (preoperative chemoradiation)
Number of subjects: 38
Study: 21235683

Group type: EXPERIMENTAL
Intervention: folinic acid/fluorouracil/irinotecan
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: folinic acid/fluorouracil/irinotecan + recombinant human endostatin
Number of subjects: 41
Study: 18294023

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16503693

Group type: EXPERIMENTAL
Intervention: High-intensity strength training group (STG)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Local muscle endurance training group (ETG)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 180
Study: 15160576

Group type: EXPERIMENTAL
Intervention: Hyalofill-F plus compression bandaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adherent gauze plus compression therapy
Number of subjects: 0
Study: 11176329

Group type: EXPERIMENTAL
Intervention: Oral rehydration solution (ORS) with smectite
Number of subjects: 804

Group type: COMPARATOR
Intervention: Oral rehydration solution (ORS) alone
Number of subjects: 804
Study: 9847464

Group type: EXPERIMENTAL
Intervention: Electron beam treatment (9/12 MeV and 12 MeV) to chest wall and drainage area, 50 Gy over 5 weeks at 2 Gy per fraction.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (Cyclophosphamide, Methotrexate, and 5-Fluorouracil) for pre-menopausal patients with axillary node involvement.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen 10 mg bid for post-menopausal patients.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiation therapy (Electron beam)
Number of subjects: 50
Study: 8008800

Group type: EXPERIMENTAL
Intervention: 8-week cognitive-behavioral course
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 150
Study: 2643331

Group type: EXPERIMENTAL
Intervention: Acetazolamide tablets (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetazolamide Sequels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methazolamide tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous treatment with carbonic anhydrase inhibitors
Number of subjects: 0
Study: 788494

Group type: EXPERIMENTAL
Intervention: Zinc supplemented formula (4 mg/liter of zinc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc supplemented formula
Number of subjects: 0
Study: 30676819

Group type: EXPERIMENTAL
Intervention: Hyperoxic preconditioning (pure oxygen for 5 min prior to balance test)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nonhyperoxic preconditioning (chamber air for 5 min prior to balance test)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hyperoxic preconditioning
Number of subjects: 19
Study: 27883201

Group type: EXPERIMENTAL
Intervention: VIA-2291 (25 mg, 50 mg, 100 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 26361971

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus bevacizumab
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Bevacizumab alone
Number of subjects: 837

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 837
Study: 23913103

Group type: EXPERIMENTAL
Intervention: Salud y Bienestar program (diabetes education delivered by community health promoters)
Number of subjects: 1413
Study: 20577750

Group type: EXPERIMENTAL
Intervention: Vaginal suppositories containing genistein (97 μg daily for 15 days/month for 3 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Vaginal suppositories containing hyaluronic acid (5 mg daily for 15 days/month for 3 months)
Number of subjects: 62
Study: 19344224

Group type: EXPERIMENTAL
Intervention: Intravenous EPO (30,000 U) every 48 hours for a total of 90,000 U
Number of subjects: 80
Study: 16765169

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally 1 hour before UDS
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 192
Study: 16281654

Group type: EXPERIMENTAL
Intervention: alendronate/calcium (10 mg/600 mg day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: placebo/calcium
Number of subjects: 145
Study: 11353880

Group type: EXPERIMENTAL
Intervention: Nutri-Expert system
Number of subjects: 557

Group type: COMPARATOR
Intervention: Traditional management (seven nutritional visits over the year)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Both groups (Nutri-Expert and traditional management)
Number of subjects: 557
Study: 9204353

Group type: EXPERIMENTAL
Intervention: iopentol
Number of subjects: 73

Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 73
Study: 8109217

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (serum ethanol concentration of 0.98 +/- 0.22 g/l)
Number of subjects: 13
Study: 3311904

Group type: EXPERIMENTAL
Intervention: Single 1 g dose tetracycline
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Single 2 g dose tetracycline
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Multiple dose tetracycline (500 mg every six hours, four times)
Number of subjects: 118

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 118
Study: 31906054

Group type: EXPERIMENTAL
Intervention: Flipped learning
Number of subjects: 119

Group type: COMPARATOR
Intervention: Traditional methodology
Number of subjects: 119
Study: 29613816

Group type: EXPERIMENTAL
Intervention: ACLR knee
Number of subjects: 43
Study: 26732944

Group type: EXPERIMENTAL
Intervention: CINV control (total control: no vomiting, no nausea, and no rescue medication)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: CINV control (no vomiting)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: CINV control rates in acute and delayed periods
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Inclusion of nausea measures in primary study outcome
Number of subjects: 177
Study: 24622816

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) performed three times daily for 5 days at a dosage of 1.4 J/cm(2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 54
Study: 22297422

Group type: EXPERIMENTAL
Intervention: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 4 weeks apart)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Brucella abortus strain RB51 vaccine (recommended vaccine dose twice 18 weeks apart)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (control group, once)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both selective media used for isolation of RB51
Number of subjects: 32
Study: 19562997

Group type: EXPERIMENTAL
Intervention: Splenic autotransplantation combined with lower esophagus transaction anastomosis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Splenectomy combined with lower esophagus transaction anastomosis
Number of subjects: 36
Study: 17451339

Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic nephrectomy (RN) for giant hydronephrosis (GH); mean operating time 126 minutes (range 65-240 minutes), estimated blood loss 101 mL (range 5-450 mL), mean length of hospital stay 2.9 days (range 1.5-6 days).
Number of subjects: 11

Group type: COMPARATOR
Intervention: Retroperitoneoscopic nephrectomy (RN) for small nonfunctioning kidneys (SNFK); mean operating time 116 minutes (range 55-270 minutes), estimated blood loss 46 mL (range 5-400 mL), mean length of stay 2.8 days (range 1-5 days).
Number of subjects: 11
Study: 15694571

Group type: EXPERIMENTAL
Intervention: Appropriate care with hylan G-F 20 (AC+H)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Appropriate care without hylan G-F 20 (AC)
Number of subjects: 255
Study: 11948386

Group type: EXPERIMENTAL
Intervention: Turning during phototherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine position during phototherapy
Number of subjects: 30
Study: 9829838

Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage-colony-stimulating factor (GM-CSF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Non-GM-CSF
Number of subjects: 18
Study: 7667561

Group type: EXPERIMENTAL
Intervention: Bayesian interpretation of the penalized likelihood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymptotic distribution of the maximum penalized likelihood estimates
Number of subjects: 0
Study: 2763811

Group type: EXPERIMENTAL
Intervention: Hypoxia at 12,500 ft (3810 m)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hypoxia at 15,000 ft (4572 m)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall response from sea level to all four altitudes
Number of subjects: 40
Study: 779465

Group type: EXPERIMENTAL
Intervention: Live, oral, streptomycin-dependent Shigella sonnei vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31088893

Group type: EXPERIMENTAL
Intervention: Starting Early Program (early child obesity prevention intervention)
Number of subjects: 100
Study: 28170098

Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 57
Study: 25600248

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24405838

Group type: EXPERIMENTAL
Intervention: Spironolactone (25mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Furosemide (20mg/day)
Number of subjects: 16
Study: 22950667

Group type: EXPERIMENTAL
Intervention: Iota-carrageenan nasal spray (0.12%)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 153
Study: 19574171

Group type: EXPERIMENTAL
Intervention: Maylard incision
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 80
Study: 17414581

Group type: EXPERIMENTAL
Intervention: Nifedipine microgranules (NMG) 30 mg/day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Nifedipine osmotic pump (NOP) 30 mg/day
Number of subjects: 192
Study: 15191321

Group type: EXPERIMENTAL
Intervention: Generalized Dynamic Fuzzy Neural Networks (GDFNN)
Number of subjects: 343